Form 4: Monopar Therapeutics CEO Chandler Robinson Reports Stock Transactions
SEC Form 4 Filing
Chandler Robinson, CEO of Monopar Therapeutics, reports the acquisition and disposal of common stock and restricted stock units related to vesting.
Summary
- On March 31, 2024, Chandler Robinson, CEO of Monopar Therapeutics, reported transactions involving the company's stock.
- These transactions included the acquisition of 24,474 shares of common stock upon the vesting and settlement of restricted stock units.
- Additionally, 7,172 shares were withheld by the issuer to cover withholding taxes related to the vesting of these units at a price of $0.681.
- Following these transactions, Robinson directly owns 166,130.8 shares of common stock.
- Robinson may be deemed to share voting and dispositive power over 4,111,272.88 shares held by Tactic Pharma LLC through TacticGem LLC and 166,667 shares directly owned by Tactic Pharma LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.
- The reported transactions also involve restricted stock units granted on January 26, 2021 (63,060 units), February 2, 2022 (159,522 units), and February 1, 2023 (169,012 units), which vest in installments.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and does not inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increase in outstanding shares from the vesting of restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 01/26/2021 | Reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. |
| 02/02/2022 | Reporting person was granted 159,522 restricted stock units, vesting 6/48ths (19,940 shares) on June 30, 2022, and 3/48ths (9,970 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. |
| 02/01/2023 | Reporting person was granted 169,012 restricted stock units, vesting 6/48ths (21,127 shares) on June 30, 2023, and 3/48ths (10,563 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. |
| 03/31/2024 | Date of earliest transaction: acquisition of common stock and disposal of shares for tax withholding. |
| 04/02/2024 | Date of Form 4 filing. |
| 12/31/2024 | Restricted stock units granted on January 26, 2021 are fully vested. |
| 12/31/2025 | Restricted stock units granted on February 2, 2022 are fully vested. |
| 12/31/2026 | Restricted stock units granted on February 1, 2023 are fully vested. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.